Last reviewed · How we verify
Botulinum Toxin Type A Injection [HG102]
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.
At a glance
| Generic name | Botulinum Toxin Type A Injection [HG102] |
|---|---|
| Also known as | HG102 |
| Sponsor | Hugel |
| Drug class | Neurotoxin; botulinum toxin preparation |
| Target | SNARE proteins (synaptobrevin/VAMP); acetylcholine release machinery |
| Modality | Small molecule |
| Therapeutic area | Neurology; Aesthetics; Pain Management |
| Phase | Phase 3 |
Mechanism of action
Botulinum toxin type A is a neurotoxin that irreversibly cleaves SNARE (soluble N-ethylmaleimide-sensitive factor attachment receptor) proteins required for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, resulting in temporary flaccid paralysis of injected muscles. The effect is reversible over 3-4 months as new nerve terminals form.
Approved indications
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
- Chronic migraine
- Spasticity
- Hyperhidrosis
- Cosmetic facial wrinkles
Common side effects
- Injection site pain or bruising
- Headache
- Muscle weakness or paralysis (off-target)
- Ptosis (eyelid drooping)
- Dry mouth
- Neck pain
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botulinum Toxin Type A Injection [HG102] CI brief — competitive landscape report
- Botulinum Toxin Type A Injection [HG102] updates RSS · CI watch RSS
- Hugel portfolio CI